Background and Study Design in Lenalidomide-Refractory MM
What defines lenalidomide-refractory multiple myeloma (MM) in this study?
Anotacoes
Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database Binod Dhakal,1 Hermann Einsele, 2 Jordan M. Schecter, 3 William Deraedt,4 Nikoletta Lendvai, 3 Ana Slaughter, 5 Carolina Lonardi, 6 Sandhya Nair,4 Jianming He,7 Akshay Kharat, 8 Patricia Cost, 7 Satish Valluri, 7 and Kwee Yong 9 1 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI; 2 Department of Internal Medicine II, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany; 3 Janssen Research & Development, Raritan, NJ; 4 Janssen Pharmaceutica NV, Beerse, Belgium; 5 Cilag GmbH International, Zug, Switzerland; 6 Janssen, Buenos Aires, Argentina; 7 Janssen Global Services, LLC, Raritan, NJ; 8 Janssen Scientific Affairs, LLC, Horsham, PA; and 9 Department of Haematology, Cancer Institute, University College London Cancer Institute, London, United Kingdom Key Points • Real-world patients with lenalidomide- refractory MM and 1 to 3 prior LOT progress rapidly through therapies. • Outcomes remain suboptimal, despite greater use of newer combination therapies, highlighting the need for early use of novel treat...
Estude com jogos interativos
Envie suas anotacoes e gere flashcards, provas e mais com IA
Comecar gratis